{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:27:04Z","timestamp":1760909224111,"version":"3.38.0"},"reference-count":60,"publisher":"JLE","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.nephro.2019.05.006","type":"journal-article","created":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T14:04:10Z","timestamp":1576245850000},"page":"19-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Toxicit\u00e9s r\u00e9nales des inhibiteurs des points de contr\u00f4le de l\u2019auto-immunit\u00e9"],"prefix":"10.1684","volume":"16","author":[{"given":"Hassan","family":"Izzedine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Gueutin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18929","reference":[{"key":"10.1016\/j.nephro.2019.05.006_bib0305","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nephro.2019.05.006_bib0310","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1053\/j.ajkd.2016.02.057","article-title":"Association of acute interstitial nephritis with programmed cell death 1\u00a0inhibitor therapy in lung cancer patients","volume":"68","author":"Shirali","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2019.05.006_bib0315","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2019.05.006_bib0320","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000455014","article-title":"Adverse renal effects of immune checkpoint inhibitors: a narrative review","volume":"45","author":"Wanchoo","year":"2017","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.nephro.2019.05.006_bib0325","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMc0904283","article-title":"Anti-CTLA4\u00a0antibody induced lupus nephritis","volume":"361","author":"Fadel","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2019.05.006_bib0330","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12882-016-0408-2","article-title":"Nivolumab-associated acute glomerulonephritis: a case report and literature review","volume":"17","author":"Jung","year":"2016","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.nephro.2019.05.006_bib0335","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ekir.2018.10.017","article-title":"Immune check point inhibitor-associated glomerulonephritis","volume":"4","author":"Ashour","year":"2019","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.nephro.2019.05.006_bib0340","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.nephro.2019.05.006_bib0345","first-page":"936","article-title":"Renal effects of immune checkpoint inhibitors","volume":"32","author":"Izzedine","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2019.05.006_bib0350","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1681\/ASN.2018050488","article-title":"Nephrotoxicity of cancer immunotherapies: past, present and future","volume":"29","author":"Perazella","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2019.05.006_bib0355","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/ckj\/sfy100","article-title":"Renal toxicities associated with pembrolizumab","volume":"12","author":"Izzedine","year":"2019","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nephro.2019.05.006_bib0360","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40425-018-0478-8","article-title":"Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience","volume":"7","author":"Mamlouk","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.nephro.2019.05.006_bib0365","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/bjc.2016.358","article-title":"Acute interstitial nephritis related to immune checkpoint inhibitors","volume":"115","author":"Belliere","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.nephro.2019.05.006_bib0370","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10637-014-0092-7","article-title":"Kidney injuries related to ipilimumab","volume":"32","author":"Izzedine","year":"2014","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.nephro.2019.05.006_bib0375","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40425-016-0205-2","article-title":"Interstitial nephritis in melanoma patients secondary to PD-1\u00a0checkpoint inhibitor","volume":"5","author":"Escandon","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.nephro.2019.05.006_bib0380","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/ckj\/sfw024","article-title":"Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma","volume":"9","author":"Murakami","year":"2016","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nephro.2019.05.006_bib0385","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40425-017-0261-2","article-title":"Acute interstitial nephritis after sequential ipilumumab\u00a0\u2013\u00a0nivolumab therapy of metastatic melanoma","volume":"5","author":"Bottlaender","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.nephro.2019.05.006_bib0390","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.2169\/internalmedicine.0444-17","article-title":"The analysis of renal infiltrating cells in acute tubulointerstitial nephritis induced by anti-PD-1\u00a0antibodies: a case report and review of the literature","volume":"57","author":"Tabei","year":"2018","journal-title":"Intern Med"},{"key":"10.1016\/j.nephro.2019.05.006_bib0395","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s13730-017-0269-y","article-title":"Tubulointerstitial nephritis as adverse effect of programmed cell death 1\u00a0inhibitor, nivolumab, showed distinct histological findings","volume":"6","author":"Uchida","year":"2017","journal-title":"CEN Case Rep"},{"key":"10.1016\/j.nephro.2019.05.006_bib0400","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1097\/MJT.0b013e3182a32ddc","article-title":"Ipilimumab granulomatous interstitial nephritis","volume":"22","author":"Thajudeen","year":"2015","journal-title":"Am J Ther"},{"key":"10.1016\/j.nephro.2019.05.006_bib0405","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1445952","article-title":"Acute tubulointerstitial nephritis associated with atezolizumab, an anti-programmed death-ligand\u00a01 (pd-l1) antibody therapy","volume":"7","author":"Xipell","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.nephro.2019.05.006_bib0410","first-page":"4607","article-title":"Ipilimumab-induced immune-related renal failure\u00a0\u2013\u00a0a case report","volume":"32","author":"Forde","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.nephro.2019.05.006_bib0415","first-page":"300","article-title":"Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis","volume":"2","author":"Jolly","year":"2009","journal-title":"NDT Plus"},{"key":"10.1016\/j.nephro.2019.05.006_bib0420","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/cncr.25639","article-title":"Phase\u00a01\u00a0dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma","volume":"117","author":"Rini","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.nephro.2019.05.006_bib0425","article-title":"Renal tubular acidosis an adverse effect of PD-1\u00a0inhibitor immunotherapy","volume":"2018","author":"El Bitar","year":"2018","journal-title":"Case Rep Oncol Med"},{"key":"10.1016\/j.nephro.2019.05.006_bib0430","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/cncr.27969","article-title":"MDX010-20\u00a0Investigators. Patterns of onset and resolution of immunerelated adverse events of special interest with ipilimumab: detailed safety analysis from a phase\u00a03\u00a0trial in patients with advanced melanoma","volume":"119","author":"Weber","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.nephro.2019.05.006_bib0435","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.nephro.2019.05.006_bib0440","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2215\/CJN.03230314","article-title":"M2\u00a0macrophage infiltrates in the early stages of ANCA-associated pauciimmune necrotizing GN","volume":"10","author":"Zhao","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2019.05.006_bib0445","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.it.2004.09.015","article-title":"The chemokine system in diverse forms of macrophage activation and polarization","volume":"25","author":"Mantovani","year":"2004","journal-title":"Trends Immunol"},{"key":"10.1016\/j.nephro.2019.05.006_bib0450","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/kisup.2014.7","article-title":"Macrophages promote renal fibrosis through direct and indirect mechanisms","volume":"2011","author":"Nikolic-Paterson","year":"2014","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.nephro.2019.05.006_bib0455","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/nep.12226","article-title":"Omeprazole-induced acute interstitial nephritis: a possible Th1-Th17-mediated injury?","volume":"19","author":"Berney-Meyer","year":"2014","journal-title":"Nephrology"},{"key":"10.1016\/j.nephro.2019.05.006_bib0460","first-page":"415","article-title":"Quantification and localization of M2\u00a0macrophages in human kidneys with acute tubular injury","volume":"7","author":"Palmer","year":"2014","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"10.1016\/j.nephro.2019.05.006_bib0465","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1365-2559.2011.03742.x","article-title":"Identification of alternatively activated macrophages in new-onset paediatric and adult immunoglobulin\u00a0A nephropathy: potential role in mesangial matrix expansion","volume":"58","author":"Ikezumi","year":"2011","journal-title":"Histopathology"},{"key":"10.1016\/j.nephro.2019.05.006_bib0470","article-title":"Nivolumab induced renal failure with collapsing focal segmental glomerulosclerosis (FSGS)","volume":"27","author":"Ray","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2019.05.006_bib0475","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1053\/j.ajkd.2017.04.026","article-title":"Nephrotic syndrome with cancer immunotherapies: a report of 2\u00a0cases","volume":"70","author":"Kitchlu","year":"2017","journal-title":"AmJ Kidney Dis"},{"key":"10.1016\/j.nephro.2019.05.006_bib0480","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.kint.2015.11.028","article-title":"Ipilimumab-associated minimal-change disease","volume":"89","author":"Kidd","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2019.05.006_bib0485","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1186\/s12885-016-2718-y","article-title":"Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma","volume":"16","author":"Bickel","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.nephro.2019.05.006_bib0490","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12882-018-0958-6","article-title":"Minimal change disease associated with anti-PD1\u00a0immunotherapy: a case report","volume":"19","author":"Gao","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.nephro.2019.05.006_bib0495","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/CJI.0000000000000189","article-title":"Nivolumab-associated nephrotic syndrome in a patient with renal cell carcinoma: a case report","volume":"40","author":"Daanen","year":"2017","journal-title":"J Immunother"},{"key":"10.1016\/j.nephro.2019.05.006_bib0500","article-title":"Membranous nephropathy related to the checkpoint inhibitor nivolumab","volume":"27","author":"Jonathan","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2019.05.006_bib0505","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2169\/internalmedicine.9814-17","article-title":"A case of IgA nephropathy after nivolumab therapy for postoperative recurrence of lung squamous cell carcinoma","volume":"57","author":"Kishi","year":"2018","journal-title":"Intern Med"},{"key":"10.1016\/j.nephro.2019.05.006_bib0510","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/rheumatology\/kew063","article-title":"Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition","volume":"55","author":"van den Brom","year":"2016","journal-title":"Rheumatology"},{"key":"10.1016\/j.nephro.2019.05.006_bib0515","article-title":"Granulomatosis with polyangitis assosciated with immune checkpoint blockade: case report and literature review","author":"Ina Cusnir","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nephro.2019.05.006_bib0520","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/ndt\/gfy105","article-title":"Programmed cell death protein\u00a01\u00a0inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis","volume":"34","author":"Manohar","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2019.05.006_bib0525","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s11523-016-0426-9","article-title":"Severe hyponatremia and immune nephritis following an initial infusion of nivolumab","volume":"11","author":"Vandiver","year":"2016","journal-title":"Target Oncol"},{"key":"10.1016\/j.nephro.2019.05.006_bib0530","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1210\/jc.2017-01905","article-title":"Anti-PD-L1\u00a0treatment induced central diabetes insipidus","volume":"103","author":"Zhao","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.nephro.2019.05.006_bib0535","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11102-009-0193-z","article-title":"Anti-CTLA-4\u00a0antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes","volume":"13","author":"Dillard","year":"2010","journal-title":"Pituitary"},{"key":"10.1016\/j.nephro.2019.05.006_bib0540","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1053\/j.ackd.2016.08.002","article-title":"The bad and the good news on cancer immunotherapy: implications for organ transplant recipients","volume":"23","author":"Maggiore","year":"2016","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.nephro.2019.05.006_bib0545","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ctrv.2017.12.004","article-title":"Cancer immunotherapy in a neglected population: the current use and future of T-cell-mediated checkpoint inhibitors in organ transplant patients","volume":"63","author":"Chae","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.nephro.2019.05.006_bib0550","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1056\/NEJMc1614298","article-title":"Preserved renal-allograft function and the PD-1\u00a0pathway inhibitor nivolumab","volume":"376","author":"Barnett","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2019.05.006_bib0555","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/CJI.0000000000000188","article-title":"Safe administration of an anti-PD-1\u00a0antibody to kidney-transplant patients: 2\u00a0clinical cases and review of the literature","volume":"40","author":"Winkler","year":"2017","journal-title":"J Immunother"},{"key":"10.1016\/j.nephro.2019.05.006_bib0560","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1093\/annonc\/mdx409","article-title":"Tumor regression and preservation of graft function after combination with anti-PD-1\u00a0immunotherapy without immunosuppressant titration","volume":"28","author":"Wu","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.nephro.2019.05.006_bib0565","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1200\/JOP.2017.027326","article-title":"Complete tumor response to pembrolizumab and allograft preservation in renal allograft recipient on immunosuppressive therapy","volume":"14","author":"Sadaat","year":"2018","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.nephro.2019.05.006_bib0570","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1097\/TP.0000000000001861","article-title":"Severe allograft rejection and autoimmune hemolytic anemia after anti-PD1\u00a0therapy in a kidney transplanted patient","volume":"101","author":"Deltombe","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2019.05.006_bib0575","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jdcr.2017.06.005","article-title":"Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade","volume":"3","author":"Miller","year":"2017","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.nephro.2019.05.006_bib0580","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/CCO.0000000000000505","article-title":"Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?","volume":"31","author":"De Bruyn","year":"2019","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.nephro.2019.05.006_bib0585","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of programmed death-1\u00a0pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nephro.2019.05.006_bib0590","series-title":"Clinical Practice Guidelines in Oncology. Management of immunotherapy-related toxicities, Vol.\u00a014","first-page":"2018","author":"NCCN","year":"2018"},{"key":"10.1016\/j.nephro.2019.05.006_bib0595","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","article-title":"Toxicities of immunotherapy for the practitioner","volume":"33","author":"Weber","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nephro.2019.05.006_bib0300","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1\u00a0antibody therapy","volume":"45","author":"Eigentler","year":"2016","journal-title":"Cancer Treat Rev"}],"container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725519305280?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725519305280?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2019.05.006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T15:27:24Z","timestamp":1741188444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725519305280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1769725519305280"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2019.05.006","relation":{},"ISSN":["1769-7255"],"issn-type":[{"type":"print","value":"1769-7255"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicit\u00e9s r\u00e9nales des inhibiteurs des points de contr\u00f4le de l\u2019auto-immunit\u00e9","name":"articletitle","label":"Article Title"},{"value":"N\u00e9phrologie & Th\u00e9rapeutique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nephro.2019.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 francophone de n\u00e9phrologie, dialyse et transplantation.","name":"copyright","label":"Copyright"}]}}